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Defining functional domains and amino acid residues in G protein coupled receptors
(GPCRs) represent an important way to improve rational drug design for this major
class of drug targets. The cannabinoid type 1 (CB1) receptor is one of the most
abundant GPCRs in the central nervous system and is involved in many physiological
and pathophysiological processes. Interestingly, cannabinoid type 1 receptor with a
phenylalanine 238 to leucine mutation (CB1F238L) has been already linked to a
number of both in vitro and in vivo alterations. While CB1F238L causes significantly
reduced presynaptic neurotransmitter release at the cellular level, behaviorally this
mutation induces increased risk taking, social play behavior and reward sensitivity
in rats. However, the molecular mechanisms underlying these changes are not fully
understood. In this study, we tested whether the F238L mutation affects trafficking
and axonal/presynaptic polarization of the CB1 receptor in vitro. Steady state or
ligand modulated surface expression and lipid raft association was analyzed in human
embryonic kidney 293 (HEK293) cells stably expressing either wild-type cannabinoid
type 1 receptor (CB1wt) or CB1F238L receptor. Axonal/presynaptic polarization of the
CB1F238L receptor was assessed in transfected primary hippocampal neurons. We
show that in vitro the CB1F238L receptor displays increased association with lipid rafts,
which coincides with increased lipid raft mediated constitutive endocytosis, leading to
a reduction in steady state surface expression of the CB1F238L receptor. Furthermore,
Abbreviations: A/D ratio, polarization index for surface CB1 receptor axonal polarization; CB1, cannabinoid type 1
receptor; CB1F238L, cannabinoid type 1 receptor with a phenylalanine 238 to leucine mutation; CB1wt, wild-type
cannabinoid type 1 receptor; CP-55940, 2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl)-5-(2-methyloctan-2-yl)
phenol;HA,hemagglutinin;MβCD,methyl-β-cyclodextrine; SR141716,5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-
N-piperidin-1-ylpyrazole-3-carboxamide; TMH4, transmembrane helix 4; WIN-55212-2, (11R)-2-methyl-11-(morpholin-
4-ylmethyl)-3-((naphthalen-1-yl)carbonyl)-9-oxa-1-azatricyclo(6.3.1.0) dodeca-2,4(12),5,7-tetraene.
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the CB1F238L receptor showed increased axonal polarization in primary hippocampal
neurons. These data demonstrate that endocytosis of the CB1 receptor is an important
mediator of axonal/presynaptic polarization and that phenylalanine 238 plays a key role
in CB1 receptor trafficking and axonal polarization.
Keywords: CB1, endocytosis, lipid raft, axonal polarization, point mutation
INTRODUCTION
The cannabinoid type 1 (CB1) receptor is an attractive target
for therapeutic drugs because it plays an important role in
the regulation of numerous physiological processes, including
neural development (Maccarrone et al., 2014), the regulation
of synaptic processes (Soltesz et al., 2015) and of various
behaviors, e.g., learning and memory (Lutz, 2009; Ruehle
et al., 2012), food intake (Silvestri and Di Marzo, 2013), and
addiction (Moreira et al., 2015). It is also associated with
many psychiatric disorders and neuropathological conditions
(Pacher et al., 2006). In all these processes, CB1 receptor is
key in the retrograde negative feedback of neurotransmission
that the endocannabinoid system exerts. Additionally, the ample
expression of this receptor in many brain areas and neural
cell types makes the CB1 receptor a promising candidate in
the treatment of pathological/dysregulated neuronal processes.
An important approach for rational drug design is to identify
residues and domains that are crucial for receptor function.
Within the CB1 receptor there are defined domains involved
in ligand binding (McAllister et al., 2003; Kapur et al., 2008;
Shim et al., 2011), switching between active and inactive
form (Nie and Lewis, 2001; Ahn et al., 2013; Marcu et al.,
2013; Scott et al., 2013), and G-protein binding (Shim et al.,
2013). Specific phosphorylation sites of the C-terminal tail of
the CB1 receptor have been implicated in the regulation of
CB1 receptor endocytosis and post-endocytic trafficking (Garcia
et al., 1998; Hsieh et al., 1999; Jin et al., 1999; Daigle et al.,
2008). Furthermore, mutations in the second extracellular loop
and helix 8 (Ahn et al., 2009, 2010), as well as truncation of the
N-terminus (Andersson et al., 2003) have been shown to affect
CB1 receptor forward trafficking.
Endocytosis is a fundamental process in the regulation of
G protein coupled receptors (GPCRs), being particularly needed
for the appropriate termination of the molecular cascade that
is triggered upon receptor activation. Similar to many other
GPCRs, the CB1 receptor is subjected to agonist induced
and/or constitutive endocytosis, and is subsequently degraded in
lysosomes or recycled back to the plasma membrane (reviewed
Rozenfeld, 2011). Intriguingly, constitutive (D’Antona et al.,
2006; Leterrier et al., 2006; McDonald et al., 2007) and/or
activity dependent (Simon et al., 2013) endocytosis has also been
reported to play amajor role in CB1 receptor axonal polarization.
However, how these compartment-specific differences arise
remains to be clarified. CB1 receptor internalization is mediated
by both clathrin coated pit and caveolae/lipid raft mediated
endocytosis (Keren and Sarne, 2003; Wu et al., 2008).
Clathrin-mediated endocytosis of the CB1 receptor proceeds
via a canonical G-protein-coupled receptor kinase mediated
pathway, whose activation recruits β-arrestin 2 and other
clathrin adapter proteins to direct receptor endocytosis (Hsieh
et al., 1999; Jin et al., 1999; Ahn et al., 2013). However,
the events leading to caveolae/lipid raft mediated endocytosis
are less well understood. Caveolae/lipid rafts are a subset
of membrane domains, consisting of a unique combination
of lipids, including cholesterol and sphingolipids (reviewed
Parton and Simons, 2007). The CB1 receptor is present in
lipid rafts (Sarnataro et al., 2005; Asimaki et al., 2011) and
co-localizes and interacts with the scaffolding protein caveolin-1
(Bari et al., 2008). The CB1 receptor contains three cholesterol
recognition domains, which may be important for association
with lipid rafts (Epand et al., 2006). Indeed, mutation of a
lysine (L402), present in one cholesterol recognition domain
of the CB1 receptor into the corresponding residue (glycine)
in the cannabinoid type 2 receptor (which is not associated
with lipid rafts), reduces lipid raft association (Oddi et al.,
2011). However, whether this mutation affects caveolae/lipid
raft mediated endocytosis of the receptor has not been
reported.
Recently, a point mutation induced in Fischer rat has
been described by Schneider et al. (2015), in which the
phenylalanine 238 in the transmembrane helix 4 (TMH4) of
the CB1 receptor is substituted by a leucine (cannabinoid
type 1 receptor with a phenylalanine 238 to leucine mutation,
CB1F238L). Computational analyses suggested that the mutant
receptor is more labile to undergo changes in transmembrane
regions that are associated with receptor activation and can
thus be described as hypersensitive. Consistent with this,
Schneider et al. (2015) reported an increase in cannabinoid
stimulated [35S]GTPγS binding of the mutant receptor. They
also demonstrated reduced presynaptic transmitter release
probability in electrophysiological experiments and increased
risk taking, social play behavior and reward sensitivity in the
mutant rats. Importantly, in this mutant, no significant changes
in the endocannabinoid system were detected other than the
mutation in the CB1 receptor (Schneider et al., 2015).
Here, we examined trafficking of the CB1F238L mutant
receptor using human embryonic kidney 293 (HEK293)
cells stably expressing hemagglutinin (HA)-tagged wild-type
CB1 (HA-CB1wt) or HA-tagged CB1F238L (HA-CB1F238L)
and transiently transfected primary hippocampal neurons.
We demonstrate that the mutant receptor shows increased
basal internalization in HEK293 cells, which depends on
caveolae/lipid raft mediated endocytosis. This finding is
consistent with an increased lipid raft association of the
CB1F238L receptor. Finally, the mutant receptor shows an
increased surface polarization towards the axon in primary
hippocampal neurons.
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MATERIALS AND METHODS
pcDNA3-HA-CB1 Constructs
BamHI and NotI restriction sites, a Kozak sequence as well
as an N-terminal human influenza HA tag were added to the
rat CB1wild-type (CB1wt) or rat CB1F238L sequence by PCR
using the following primers: forward GCGGATCCACCATGG
CATACCC-ATATGATGTCCCCGACTACGCGAAGTCGATC
CTA-GATGGCCTTG, reverse GGCGC-GGCCGCTCACAGA
GCCTCGGCGGA. The resulting sequence was cloned into the
expression vector pcDNA3 using the restriction sites BamHI and
NotI.
Cell Lines Stably Expressing HA-CB1
HEK293 cells were grown in DMEM (Invitrogen) containing
10% fetal calf serum (A15-101, PAA The Cell Culture Company),
Penicilin/Streptamycin, sodium butyrate and non-essential
amino acids (all from Gibco Life Technologies). To establish
cell lines stably expressing HA-CB1wt or HA-CB1F238L
HEK293 cells were transfected with 24 µg of linearized
DNA using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions. Forty-eight hours after transfection,
selection medium containing 1 mg/ml G418 (Geneticin) was
added to the cells. To generate clones of resistant cells a limited
dilution approach in 96-well plates was used. Clones were
picked from those wells that originally contained only a single
cell. To examine homogenous expression of HA-CB1 in the
picked colonies immunocytochemistry was performed using a
monoclonal antibody against the HA epitope of the receptor.
Expression levels of HA-CB1 were determined by western blot
analysis using a monoclonal antibody against the HA epitope
of the receptor and subsequent normalization against actin.
Those clones were chosen which showed intermediate receptor
expression as compared to all clones which were generated.
Furthermore, the chosen clones showed similar expression levels
for both lines.
Primary Hippocampal Neurons
Embryonic rat hippocampal neurons were prepared as
described (Girach et al., 2013). At 5 days in vitro (DIV)
cells were transfected with 0.75 µg of HA-CB1wt or
HA-CB1F238L constructs using Lipofectamine 2000 according
to manufacturer’s instructions. After 48 h cells were used for the
polarization assay. Because our work is not recovery halothane
anesthesia and immediate euthanasia not involving pain, it is
designated as schedule 1 by the Home Office and it does not need
Home Office licensing. All our work is overseen by, and fully
conforms to the University of Bristol and UK ethical guidelines.
Immunocytochemistry
HEK293 cells stably expressing HA-CB1wt or HA-CB1F238L
were seeded on poly-L-lysine (Sigma) coated coverslips. After
48 h cells were washed in PBS and fixed in 4% PFA in PBS for
10 min. After washing with PBS cells were permeabilized with
0.05% Triton-X-100 in PBS for 5 min. After blocking with 4%
goat serum in PBS for 15 min primary antibody (HA.11 16B12,
MMs-101P, Covance 1:1000) in 4% goat serum was added for
2 h. After two 5 min washes with PBS, Alexa-488 conjugated
secondary antibody (A-11008 Life Technologies, 1:1000) in 4%
goat serumwas added for 30min. Subsequently cells were washed
once for 5 min and nuclei were stained with DAPI (Hoechst) for
5 min. Cells were washed once in PBS and mounted on Mowiol.
All steps were carried out at room temperature.
Trypsin Protection Assay
Trypsin protection assay was performed as described (Grimsey
et al., 2010) with slight modifications. Stable HEK293 cells
were placed in serum free medium (SFM) 1 h prior to the
experiment. For endocytosis experiments, cells were treated
either with 100µMWIN-55212-2 (BN0544, BioTrendChemicals
AG) or 100 µM SR141716 (generously provided by the NIMH
Chemical Synthesis and Drug Supply Program) in SFM for
45 min, with 20 µM PitStop2TM (Abcam) for 15 min or
5 mM methyl-β-cyclo-dextrin (MβCD; Sigma) in SFM for
30 min. WIN-55212-2, SR141716 and PitStop2TMwere dissolved
in DMSO, MβCD was dissolved in SFM. All treatments were
matched with appropriate vehicle conditions. After treatment
the medium was removed and either 2 ml of versene (15040-
033 Gibco Life Technologies) as control or trypsin solution
(25300-054 Gibco Life Technologies) were added. After 4 min
10 ml of cold DMEM containing 10% fetal calf serum,
Penicillin/Streptomycin, sodium butyrate and non-essential
amino acids were added to stop the enzymatic reaction. Cells
were pelleted and washed two times with cold PBS to remove
any residual trypsin. The pellet was resuspended in lysis
buffer (150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM
Tris, pH 7.5, 1% CHAPS, HaltTM Protease and Phosphatase
Inhibitor Cocktail, Thermo Scientific) and lysed by rotating
over night at 4◦C. Subsequently nuclei and cell debris were
removed by centrifugation at 1000 g and 4◦C for 10 min.
Protein concentration of the supernatant was determined using
a Bradford protein assay (Biorad). The lysate was analyzed by
western blot. Signals for HA were normalized against tubulin
or actin and percent intracellular CB1 receptor was calculated
by dividing normalized HA signal in trypsin treated cells by
normalized HA signal in versene treated cells and multiplied
by a hundred. In conclusion percent surface CB1 receptor was
calculated by subtracting percent intracellular CB1 receptor from
a hundred.
Lipid Raft Preparation
To prepare lipid rafts from stable HEK293 cells, a detergent
free protocol using a discontinuous sucrose gradient was used.
Cells were placed in SFM 1 h prior to the experiment. Medium
was removed and cells were scraped into cold PBS and pelleted
at 118 g and 4◦C for 5 min. The supernatant was removed
and the cell pellet was resuspended in 900 µl ice cold 45%
sucrose in TBS. After sonification with three strokes for 10 s
each (Bandelin Sonopuls HD60), the homogenate was passed
through a 25G cannula for 20 times. Eight-hundred microliter
of the homogenate was placed in an ultracentrifuge tube and
overlaid with 2700 µl of 30% sucrose in TBS and 500 µl of
5% sucrose in TBS. The sucrose gradient was centrifuged in
a Beckmann ultracentrifuge using a SW40TI rotor at 4◦C and
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100,000 g for 24 h to 26 h. Subsequently eight 400µl fractions and
one 800 µl fraction were collected from the top to the bottom.
The 800 µl bottom fraction included the resuspended pellet. 8 µl
of each fraction were analyzed by western blot. HA signals were
normalized against caveolin-1 for each fraction and normalized
HA values from fractions 2–4 were chosen as lipid raft fractions.
All other fractions were considered as non-raft fractions.
Western Blot
If not stated otherwise 20 µg of protein were separated by
electrophoresis on a 10% polyacrylamide/SDS gel. Subsequently
proteins were blotted to a nitrocellulose membrane using a
Biorad wet blot system. Membranes were stained with Ponceau
for 5 min to control for successful transfer of proteins to the
membrane. Subsequently the membranes were blocked with
5% non-fat dry milk in TBST for 1 h at room temperature
and primary antibody (HA.11 16B12, MMs-101P, Covance
1:1000; T9026 mouse anti tubulin, Sigma Aldrich, 1:200,000;
04–1040 rabbit anti actin, Millipore, 1:1000; SC-894 rabbit anti
caveolin-1, Santa Cruz, 1:1000) diluted in 5% non-fat dry milk
in TBST incubated over night at 4◦C. Primary antibody was
removed and after three 10-min washes with TBST, horseradish
peroxidase coupled secondary antibody was added in 5% non-fat
dry milk and incubated for 30 min at room temperature. After
two 10-min washes with TBST and one 10-min wash with
PBS membranes were incubated with ECL solution (Amersham
ECLTM Prime Western Blotting Detection Reagent) according
to the manufacturer’s instructions and imaged with the Peqlab
Fusion-SL system using the fusion software version 15.16 by
Vilber Lourmat. The molecular weight of western blot bands
was calculated with the same imaging software. Quantification
of western blot bands was performed using the bio1D software
version 15.02 by Vilber Lourmat.
Equilibrium Binding Assay
HEK293 cells stably expressing HA-CB1wt or HA-CB1F238L
were scraped into cold PBS and pelleted with 2000 g at 4◦C
for 4 min. After cells were resuspended in cell buffer (50 mM
Tris HCl, 1 mM EDTA and 3 mM MgCl2), the protein content
was measured by Bradford assay (Biorad). Equilibrium binding
assays were carried out using the cannabinoid receptor agonist
[3H]CP-55940, at a concentration of 0.7 nM. 1 mg/ml BSA
and 50 mM Tris buffer was used in a total assay volume of
500 µl containing 0.01% DMSO. Binding was initiated by adding
1mg/ml cells. Assays were incubated at 37◦C for 1 h. The reaction
was stopped by the addition of ice cold wash buffer that contained
50 mM Tris buffer and 1 mg/ml BSA and vacuum filtration
using a 24-well sampling manifold Brandel cell harvester and
Whatman GF/B glass-fiber filters that had been soaked in the
same wash buffer at 4◦C for at least 24 h. Each reaction tube was
washed six times with a 500 µl aliquot of buffer. The filters were
then oven dried for 1 h, and then placed in 5 ml scintillation vials
with 4 ml of scintillation fluid. Radioactivity was quantified by
liquid scintillation spectrometry. Specific binding is defined as
the difference between the binding that occurred in the presence
and absence of 1 µMCP-55940 and varied between 70%–90% of
the total binding.
Surface Polarization Assay
Surface polarization in primary hippocampal neurons was
evaluated by quantitative immunofluorescence analysis by
confocal microscopy in accordance with previous publications
(see Sampo et al., 2003; Silverman et al., 2005; Leterrier
et al., 2006; McDonald et al., 2007). Briefly, 20 µm long
segments of dendrites and axons were manually traced using
the polygon selection tool in ImageJ. Mean surface fluorescence
intensity along each segment was then measured (in the
corresponding channel), with an average of 3–5 dendritic
and axonal segments each outline per neuron. Dendrites and
axons were identified by microtubule-associated protein 2
(MAP2) positive or negative counterstaining. Morphological
classification was facilitated by restricting analysis to DIV
7–9 neurons, as these younger neurons have established polarity
but do not yet display complex dendritic arborization, making
the long thin axonal projections easily identifiable. Segments
proximal to soma are termed ‘‘proximal’’; segments near the
growth edge are termed ‘‘distal’’ and segments mid-way along
the length of the dendrite are termed ‘‘intermediate.’’ For each
condition, typically 10–15 neurons each from at least three
separate experiments were used. Each data set was evaluated
using the D-Agostino and Pearson omnibus normality test to
confirm normal population distribution (suitable for parametric
statistical analysis).
Quantitative Immunofluorescence Analysis
Transfected neurons were placed in pre-warmed HBS buffer
(25 mM HEPES, 137 mM NaCl, 5 mM KCl, 15 mM glucose,
1.5 mM CaCl2, 1.5 mM MgCl2, pH7.4, osmolarity adjusted
to within ± 10 mOsM of the culture medium) and were
allowed to adjust for 5 min at room temperature. To label
surface CB1 receptor primary mouse monoclonal HA antibody
(H3663 Sigma 1:200) in HBS buffer was added to the coverslips
for 20 min. After washing the coverslip three times in HBS
cells were fixed with pre warmed paraformaldehyde solution
(4% paraformaldehyde, 5% sucrose in PBS). After 15 min
the coverslips were washed three times in PBS and residual
paraformaldehyde was quenched by adding 50 mM ammonium
chloride in PBS for 5 min. Subsequently coverslips were
washed three times with PBS and blocked with 10% horse
serum in PBS for 10 min. Donkey anti mouse Cy3-conjugated
secondary antibody (715-165-151 Jackson Immuno 1:600)
was applied in 5% horse serum in PBS for 45 min. After
three washes with PBS cells were permeabilized with 0.1%
TritonX-100 in PBS for 10 min, washed two times with PBS
and blocked with 10% horse serum for 20 min. Primary
mouse monoclonal antibody against HA (1:400) and rabbit
polyclonal antibody against MAP2 (M3696 Sigma 1:600) in
5% horse serum were added to the coverslips for 1 h.
After washing three times with PBS, donkey anti-mouse Cy2
coupled (715-225-150 Jackson Immuno 1:600) and donkey
anti-rabbit Cy5 coupled (715–225–152 Jackson Immuno 1:600)
secondary antibodies were added for 1.5 h. Subsequently
coverslips were washed three times in PBS and mounted
in Fluoromount (Sigma). All steps were performed at room
temperature.
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Confocal Microscopy
Neurons were imaged using the 40× oil objective of a Zeiss
LSM510 UV META Axiovert 200M laser scanning microscope
and the Zeiss LSM Data Server software. Cy2 was excited with
an Argon/2 laser at 488 nm and emission was detected using
a 505–530 nm band pass filter (displayed as green channel).
Cy3 was excited with a He/Ne laser at 543 nm and emission was
detected using a 560–615 nm band pass filter (displayed as red
channel). Cy5 was excited with a He/Ne laser at 633 nm and
emission was detected using a 650 nm long pass filter (displayed
as blue channel). Z-stacks of four optical slices per cell were
recorded with 4× averaging, 1024× 1024 pixels and 8-bit depth.
If necessary multiple pictures per cell were collected to capture
the entire neuron.
Analysis
Quantification of fluorescence was performed using ImageJ
software. Maximum projections were used to quantify surface
CB1 receptor fluorescence. 20 µm × 1 µm regions of interest
(ROIs) from dendrites (MAP2+) and proximal, intermediate and
distal parts of the axon (MAP2−) were selected and fluorescence
intensity was measured for the surface CB1 receptor. To
avoid selection bias, ROIs were chosen in merged images
showing only the total CB1 receptor and MAP2 channel
data. Average axonal surface CB1 receptor was calculated
by taking the average of surface CB1 receptor in proximal,
intermediate and distal parts of the axon. Average dendritic
surface CB1 receptor was calculated by taking the average of
surface CB1 receptor in two to three different dendrites of one
cell. The surface CB1 receptor polarization index (A/D ratio)
for each cell was determined by dividing average axonal surface
CB1 receptor by average dendritic surface CB1 receptor. To
measure the gradient of surface CB1 receptor expression from
the proximal to the distal axon values for the intermediate
and distal axon were expressed as percent of the value for the
proximal axon. The experimenter was blind to the genotype
throughout the imaging and analysis procedure to avoid
any bias.
Statistics
Two-way ANOVA or repeated measures ANOVA and
Bonferroni’s post hoc test, student’s t-test and one sample
t-test were performed using GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego, CA, USA). Data are
expressed as mean± SEM.
RESULTS
Characterization of HEK293 Cells Stably
Expressing HA-CB1wt or HA-CB1F238L
HEK293 cells stably expressing HA-CB1wt or HA-CB1F238L
were quantified by western blot analysis and clones with
intermediate and similar expression levels between genotypes
FIGURE 1 | Characterization of human embryonic kidney 293 (HEK293) cells stably expressing hemagglutinin-tagged cannabinoid type 1 wild-type (HA-CB1wt) or
HA-cannabinoid type 1 receptor with a phenylalanine 238 to leucine mutation (CB1F238L). (A) Snake plot of the rat wild-type CB1 receptor with phenylalanine 238
labeled in green. Source: gpcrdb.org/ (Pándy-Szekeres et al., 2018). (B) Relative expression levels of HA-tag signal in transfected and untransfected HEK293 cells.
HA-tag signal in HEK293 cells not transfected or stably transfected with pcDNA3-HA-CB1wt were detected by western blot analysis. Four bands were detected at
78 kD, 68 kD, 51 kD and 47 kD in transfected cells. All four bands detected in the western blot are specific as they do not appear in untransfected HEK293 cells.
(C) Subcellular localization was examined by immunostaining using a monoclonal anti-HA antibody. Expression levels were quantified by western blot analysis using
a monoclonal anti-HA antibody and normalizing to actin. Two clones with moderate and similar HA-CB1 expression levels where chosen. IB, Immuno blot. (Scale
bar: 20 µm).
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were selected. Four bands of 78 kD, 68 kD, 51 kD, 47 kD were
observed in the western blot for HA-CB1 which were shown
to be specific as compared to untransfected cells (Figure 1).
The 51 kD band represents the putative CB1 monomer.
Additional bands visible in the same lane may represent receptor
dimers (Wager-Miller et al., 2002), glycosylated/deglycosylated
(De Jesús et al., 2006) or other post-translationally modified
receptors.
Using a trypsin protection assay and western blot analysis,
we quantified the surface expression of the wild-type and
mutant CB1 receptors. In short, trypsin treatment of cells
leads to the cleavage of the HA-tag of surface CB1 receptor,
whereas intracellular receptor remains unaffected. Thus,
surface and intracellular receptor can be distinguished
by HA immunoreactivity. Trypsin treatment reduced the
intensity of the two higher molecular bands but did not
affect the 47 kD and 51 kD bands (Figure 2A). This is in
accordance with the observation by Grimsey et al. (2010).
The authors state that the lower molecular bands are
deglycosylated forms of the CB1 receptor located in the
intracellular biosynthetic or degradation pathway, which
protects them from trypsin cleavage (Grimsey et al., 2010).
Additionally to the 68 kD band, which corresponds to the
64 kD band observed by Grimsey et al. (2010), we also observed
78 kD band, which might be a CB1 receptor species with
different posttranslational modification. Both, the 68 kD and
FIGURE 2 | Surface expression of HA-CB1F238L compared with HA-CB1wt.
(A) HEK293 cells stably expressing HA-CB1wt or HA-CB1F238L were treated
with trypsin or versene (control). Trypsin is able to cleave the extracellular
HA-tag. Thus, control samples show total CB1 receptor amount, whereas
trypsin treated samples show intracellular CB1 receptor amount. (B) Surface
HA-CB1 was calculated and expressed as percent of total HA-CB1. We found
85.49% (±1.44) of HA-CB1wt, but only 57.68% (±4.26) of HA-CB1F238L to
be located to the plasma membrane. (Student’s t-test. Data are presented as
the mean ± SEM of n = 7 independent experiments. ∗∗∗p < 0.001).
78 kD bands were used to quantify surface CB1 receptor
(Figure 2A). We found a significant difference in plasma
membrane localization with 85 ± 1% of HA-CB1wt but only
58 ± 4% of HA-CB1F238L being expressed on the cell surface
(Figure 2B).
HA-CB1F238L Surface Expression Can Be
Rescued by Inverse Agonist Treatment
To test if the altered surface expression of the F238L mutant
is due to differences in internalization, we examined the
endocytosis behavior of the CB1F238L receptor in response
to agonist stimulation. The cannabinoid receptor agonist
WIN-55212-2 is known to induce strong endocytosis of the
CB1 receptor (Hsieh et al., 1999; Figure 3A). WIN-55212-2
treatment (100 nM, 45 min) induced strong internalization
of both HA-CB1wt and HA-CB1F238L (Figure 3B) with no
significant difference between wild-type and mutant receptors
(Figure 3C). Interestingly, however, equilibrium binding assays
showed a decreased affinity of the mutant receptor for WIN-
55212-2 (Figures 3D,F). These data imply that the CB1F238L
mutation might alter the binding affinity for WIN-55212-2.
Conversely, inverse agonist treatment stabilizes the CB1 receptor
at the surface (Grimsey et al., 2010). We therefore tested
the effect of inverse agonist SR141716 on HA-CB1F238L
surface expression (Figure 3A). One-hundred nanomolar
SR141716 for 45 min rescued surface expression of the mutant
receptor to wild-type levels (Figure 3B). As with WIN-55212-
2, equilibrium binding assays showed a decreased affinity
of the CB1F238L receptor for SR141716. This demonstrates
that the higher effect that SR141716 has on the surface
expression of the CB1F238L receptor (Figure 3F) is not due
to an increased affinity of the mutant receptor for SR141716
(Figure 3E).
Increased Basal Endocytosis of
HA-CB1F238L Is Mediated by
Caveolae/Lipid Rafts and Not by Clathrin
Coated Pits
To test if basal endocytosis of the CB1 receptor mediates
the decreased surface expression of HA-CB1F238L, we
inhibited clathrin-mediated or caveolae/lipid raft-mediated
internalization. Cells were treated either with 20 µM PitStop2TM
for 15 min to inhibit clathrin-mediated endocytosis (Dutta et al.,
2012), or with 5 mM MβCD for 30 min, a cholesterol depleting
agent that disrupts caveolae/lipid rafts (Figure 4A). PitStop2TM
treatment did not affect surface expression of the CB1F238L
receptor. In contrast, MβCD treatment led to an increase in
surface expression of the CB1F238L receptor consistent with
decreased caveolae/lipid raft-mediated endocytosis of the mutant
receptor (Figure 4B).
We next tested if CB1F238L is enriched in biochemical
lipid raft preparations using a detergent free protocol in
a discontinuous sucrose gradient (Figure 4C). We found a
significant increase of CB1F238L receptor compared to the
CB1wt receptor in the lipid raft fractions (Figure 4D).
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FIGURE 3 | Effect of WIN-55212-2 and SR141716 on surface expression of HA-CB1F238L compared to HA-CB1wt. (A) HEK293 cells stably expressing HA-CB1wt
or HA-CB1F238L were treated either with vehicle, 100 nM WIN-55212-2 or 100 nM SR141716 for 45 min. Surface expression was analyzed by a trypsin protection
assay. (B) Strong internalization after WIN-55212-2 treatment was observed for both receptors. SR141716 treatment rescued surface expression of CB1F238L
receptor back to wild-type levels. Surface HA-CB1 was calculated and expressed as percent of total HA-CB1 as described in “Materials and Methods” section. (Two
way ANOVA and Bonferroni’s post hoc test. Data are presented as the mean ± SEM of n = 4 independent experiments. ∗∗∗p < 0.001; n.s., p > 0.05 vs. wild-type;
###p < 0.001 vs. vehicle). (C) The effect of SR141716 on surface expression is significantly increased for CB1F238L receptor (Student’s t-test between genotypes.
Data are presented as the mean ± SEM of n = 4 independent experiments. ∗p < 0.05). Competition binding experiments with radiolabeled CB1 receptor agonist
[3H]CP55940 showed that the F238L mutation causes a decrease in the affinity of CB1 receptor (D) for the agonist WIN55212-2 and (E) for the inverse agonist
SR141716. (F) In competition binding experiments with [3H]CP-55940 the CB1F238L receptor showed significantly reduced affinity for WIN-55212-2 as well as for
SR141716. (Student’s t-test of pEC50. Data are presented as the mean ± SEM of n = 3–8 independent experiments. ∗p < 0.05).
CB1F238L Receptor Shows Decreased
Surface Expression in Dendrites and
Increased Axonal Polarization
Several studies have shown that selective removal of the
CB1 receptor from the somatodendritic compartment, via a
constitutive endocytic pathway is required to maintain proper
receptor distribution and axonal surface polarization (Leterrier
et al., 2006; McDonald et al., 2007; Simon et al., 2013). As
the CB1F238L receptor shows increased constitutive endocytosis
in HEK293 cells we next evaluated the surface distribution of
CB1F238L in primary hippocampal neurons by quantitative
immunofluorescence (Figure 5). Using the axonal polarization
index (ratio of axonal to dendritic surface fluorescence; A/D
ratio) we observed an almost two-fold difference on the polarity
of the wild-type and mutant receptor (Figure 5B). We attribute
this predominantly to a significant reduction of dendritic
surface expression of CB1F238L (Figure 5C). Surprisingly,
there was a non-significant trend to reduced axonal surface
expression of CB1F238L (Figure 5D) but a significantly increased
axonal gradient for the CB1F238L receptor towards the distal
end of the axon as compared with the wild-type receptor
(Figure 5E).
DISCUSSION
The F238L point mutation in the rat CB1 receptor has
been reported to result in a hyperactive receptor on the
biochemical as well as electrophysiological and behavioral level
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FIGURE 4 | Surface expression of HA-CB1F238L compared with HA-CB1wt
after inhibition of clathrin coated pit or caveolae mediated endocytosis.
(A) HEK293 cells stably expressing HA-CB1wt or HA-CB1F238L were treated
either for 15 min with 20 µM PitStop2TM to inhibit clathrin coated pit
endocytosis or for 30 min with 5 mM methyl-β-cyclo-dextrin (MβCD) to inhibit
caveolae mediated endocytosis. Surface expression was analyzed by a trypsin
protection assay. (B) Only MβCD treatment significantly increased surface
expression of CB1F238L receptor. (Two way ANOVA and Bonferroni’s post
hoc test. Data are presented as the mean ± SEM of n = 4 independent
experiments. Surface HA-CB1 was calculated and expressed as percent of
total HA-CB1 as described in “Materials and Methods” section ∗p < 0.05;
∗∗p < 0.01; vs. wild-type; ##p < 0.01 vs. vehicle). (C) Lipid rafts were
prepared from HEK293 cells stably expressing HA-CB1wt or HA-CB1F238L
and analyzed by western blot. HA signals were normalized against caveolin
and values for caveolin rich fractions 2–4 were chosen as lipid raft fractions, all
others as non-raft fractions (see “Materials and Methods” section). cav-1,
calveolin (D) Values for CB1F238L receptor were expressed as percentage of
CB1wt receptor. (One sample t-test. Data are presented as the mean ± SEM
of n = 7 independent experiments. ∗p < 0.05; ∗∗p < 0.01).
(Schneider et al., 2015). At the cell biological level we observed
a reduction in surface expression of mutant receptor could be
eliminated by treatment of the cells with the CB1 receptor
inverse agonist SR141716. On the other hand, when cells were
treated with the CB1 receptor agonist WIN-55212-2 there was
no difference in induced internalization between wild-type and
mutant receptor. This indicates an effect of the mutation on basal
but not agonist induced internalization of the receptor. However,
we cannot exclude that there might be a difference in the kinetics
of agonist induced endocytosis.
Interestingly, equilibrium binding experiments showed a
reduced affinity of the mutant receptor for SR141716 as
well as for WIN-55212-2. However, although the CB1F238L
receptor showed reduced affinity for SR141716, the inverse
CB1 receptor agonist was still able to rescue surface expression
of the CB1F238L receptor. The observation that exchanging
an aromatic residue at position 238 of the CB1 receptor by a
non-aromatic residue entails decreased affinity for SR141716 as
well as for WIN-55212-2 is an interesting finding in itself. In
fact, an aromatic microdomain between TMH 3-4-5-6 has been
suggested to be the binding site for SR141716 as well as for WIN-
55212-2 but not for CP-55940 (McAllister et al., 2003), for which,
accordingly, we did not see any difference in affinity either (data
not shown).
To further support the concept that the mutant receptor
undergoes increased basal endocytosis, we inhibited the two
internalization pathways that have been described for the
CB1 receptor with MβCD (inhibitor of clathrin-mediated
endocytosis) and PitStop2TM (inhibitor of caveolae/lipid raft
mediated endocytosis). Although MβCD treatment has been
reported to also affect clathrin coated pit budding under certain
conditions (Rodal et al., 1999; Subtil et al., 1999), the increase
that this compound triggers in surface expression of CB1F238L
combined with the lack of effect under PitStop2TM treatment
indicates that the CB1F238L receptor undergoes increased
caveolae/lipid raft mediated rather than clathrin coated pit
mediated endocytosis. Caveolae and lipid rafts are membrane
domains characterized by a unique composition of lipids,
including cholesterol and sphingolipids (Parton and Simons,
2007). They are thought to compartmentalize scaffolding and
signaling molecules as well as playing a role in endocytosis (Allen
et al., 2007). The CB1 receptor as well as the endocannabinoids
2-arachidonoyl glycerol (2-AG) and anandamide (AEA) have
been reported to be targeted into lipid rafts (Sarnataro et al.,
2006; Dainese et al., 2007; Rimmerman et al., 2008; Asimaki
et al., 2011), and lipid raft disruption by MβCD has been shown
to affect CB1 receptor ligand as well as G-protein binding
(Bari et al., 2005a,b). Furthermore, in immunoprecipitation and
colocalization studies the CB1 receptor has been shown to
interact with caveolin-1, a protein enriched in lipid rafts and
caveolae (Bari et al., 2008). In agreement with the increased
endocytosis of the mutant receptor via caveolae/lipid rafts,
biochemical lipid raft preparations revealed a significantly higher
amount of CB1F238L receptor in the lipid raft fractions.
However, the mechanism by which mutation of phenylalanine
238 affects lipid raft allocation remains to be examined.
Possibly, the activation state or ligand binding of the receptor
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FIGURE 5 | Axonal polarization of HA-CB1wt and HA-CB1F238L in primary hippocampal neurons. Immunocytochemistry was performed using primary rat
hippocampal neurons which were transfected with either HA-CB1wt or HA-CB1F238L. (A) Surface HA-CB1 receptor is shown in red, total HA-CB1 receptor in
green and microtubule-associated protein 2 (MAP2) in blue. Surface HA-CB1 receptor was quantified in 20 × 1 µm regions of interest (ROIs) in the dendrites
(MAP2+; a), proximal axon (MAP2−; b), intermediate axon (MAP2−; c) and distal axon (MAP2−; d). (B) The polarization index (A/D) for surface CB1 receptor was
determined by dividing average axonal surface fluorescence by average dendritic surface fluorescence (Scale bar: 20 µm). (C) There is a significant reduction in
dendritic surface CB1F238L receptor. (D) In the axon, there is a small reduction in surface CB2F238L, which did not reach statistical significance though. (Student’s
t-test. Data are presented as the mean ± SEM of 21 HA-CB1wt cells and 30 HA-CB1F238L cells of two independent experiments. ∗∗p < 0.01; ∗∗∗p < 0.001).
(E) Intermediate and distal axonal surface CB1 receptor is expressed as percent of surface CB1 receptor in the proximal axon (repeated measures ANOVA and
Bonferroni’s post hoc test. Data are presented as the mean ± SEM of 19 HA-CB1wt cells and 26 HA-CB1F238L cells of two independent experiments. ∗p < 0.05).
has an influence on its lipid raft allocation, as it has been
suggested for other receptors, including the CB1 receptor
(Chini and Parenti, 2004; Sarnataro et al., 2005, 2006; Allen
et al., 2007). Another possibility is differential protein-protein
interactions of the CB1F238L receptor with lipid raft scaffolding
proteins, such as caveolin-1. Although a caveolin-1 interacting
domain containing aromatic residues has been suggested many
years ago (Couet et al., 1997), phenylalanine 238 in the
CB1 receptor is not part of such a domain. Finally, it could
also be possible that a differential interaction with membrane
lipids, such as cholesterol, plays a role here even though
phenylalanine 238 is not part of a cholesterol recognition amino
acid consensus (CRAC; cholesterol-consensus binding motif)
domain.
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Given that endocytosis of the CB1 receptor has been described
to be one crucial step for the polarization of this receptor to the
axon (Leterrier et al., 2006; McDonald et al., 2007; Simon et al.,
2013), we finally tested whether the mutant receptor polarizes
differentially within the neuronal surface. For the CB1F238L
receptor we found a significantly increased axonal polarization
(especially towards the distal axon) due to a strong decrease
in dendritic surface expression. All these findings correspond
well to predictions made by the model by Simon et al. for a
hyperactive receptor (Simon et al., 2013).
In conclusion, our study provides evidence that phenylalanine
238 plays a role in the allocation of the CB1 receptor
into lipid rafts and in the receptor’s trafficking properties.
It also hints at a possible mechanistic explanation for
CB1 receptor axonal polarization and for the first time implicates
non-clathrin-mediated constitutive endocytosis in regulating
CB1 surface distribution. Also, the CB1F238L receptor provides
a valuable tool to further study the role of caveolae/lipid rafts in
CB1 receptor trafficking.
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